Quotient BioResearch acquires BioDynamics to increase capacity and service offering

Quotient BioResearch, a leading European provider of analytical and safety evaluation services and products for bioscience and sport, has acquired BioDynamics Research, a specialist provider of metabolism, bioanalytical and radiochemistry services to the worldwide pharma and biotech industries.

BioDynamics, which has annual revenues more than £7m (Euro 9.4m) and 100 employees, is the fourth acquisition for Quotient BioResearch, which was established in early 2007. The enlarged group will have revenues in excess of £35m (€47m) and employ approximately 350 people in the UK. The Group will continue to operate from its existing sites in Newmarket, Rushden, London and Edinburgh.

In 2007 Quotient BioResearch acquired: HFL, a leading European provider of drug surveillance testing services for sport and bioanalytical and biomarker testing services to the pharmaceutical and biotechnology sectors; Alba Bioscience, a provider of diagnostic reagents, principally for blood typing; and GR Micro, a provider of microbiology and molecular biology services to the global pharma and biotechsectors.

The drug development services businesses of Quotient BioResearch will trade under the Quotient name from May 2008. The sports testing and research business of Quotient BioResearch will continue to trade as HFL. Alba Bioscience, the diagnostics reagents business of Quotient BioResearch, will continue to trade as Alba Bioscience.

"We have experienced considerable growth in demand for the drug development services we offer. The combination with BioDynamics will allow Quotient BioResearch to both increase capacity and extend the range of services it offers for the benefit of its clients," said Paul Cowan, chairman and ceo of Quotient BioResearch.

"We will be making major investments at both BioDynamics and Quotient BioResearch to further underpin our commitment to meeting the current and future requirements of our clients."